Thomson Medical Group Limited announced its results for the financial year ended Jun, 30 2026 on Aug, 28 2026, reporting revenue of 420.1 million Singapore dollars, up 6.4% from 394.7 million Singapore dollars in FY2025.

Group EBITDA grew 23.2% year on year to 67.3 million Singapore dollars, while adjusted EBITDA rose 9.9% to 82.5 million Singapore dollars, lifting the overall EBITDA margin to 16.0% from 13.8% previously. Loss after tax narrowed 40.8% to 27.8 million Singapore dollars compared with a 47.0 million Singapore dollars loss a year earlier.

As at Jun, 30 2026, the company held cash of 113.1 million Singapore dollars against total debt of 1.1 billion Singapore dollars, resulting in net debt of 994.0 million Singapore dollars and a net-debt-to-EBITDA ratio of 14.8 times. Net debt represented 1.9 times equity, which stood at 525.5 million Singapore dollars. Interest expenses for the year were 49.2 million Singapore dollars, and net cash outflow amounted to 11.4 million Singapore dollars.

By geography, FY2026 revenue comprised 192.9 million Singapore dollars from Singapore operations, 125.4 million from Malaysia and 101.3 million from Vietnam. Segment EBITDA margins were 24.3% in Singapore, 17.0% in Malaysia and 14.6% in Vietnam.

Management said the group is focusing on expanding specialty services, widening payor and cross-border access, and improving utilisation across its hospitals in Singapore, Malaysia and Vietnam.